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Abstract
Alternative pre-mRNA splicing defects can contribute to, or result from, various diseases, including cancer. Aberrant mRNAs,
splicing factors and other RNA processing factors have therefore become targets for new therapeutic interventions. Here we
report that the natural polyphenol resveratrol can modulate alternative splicing in a target-specific manner. We transfected
minigenes of several alternatively spliceable primary mRNAs into HEK293 cells in the presence or absence of 1, 5, 20 and
50 mM resveratrol and measured exon levels by semi-quantitative PCR after separation by agarose gel electrophoresis. We
found that 20 mg/ml and 50 mg/ml of resveratrol affected exon inclusion of SRp20 and SMN2 pre-mRNAs, but not CD44v5 or
tau pre-mRNAs. By Western blotting and immunofluorescence we showed that this effect may be due to the ability of
resveratrol to change the protein level but not the localization of several RNA processing factors. The processing factors that
increased significantly were ASF/SF2, hnRNPA1 and HuR, but resveratrol did not change the levels of RBM4, PTBP1 and
U2AF35. By means of siRNA-mediated knockdown we depleted cells of SIRT1, regarded as a major target of resveratrol, and
showed that the effect on splicing was not dependent on SIRT1. Our results suggest that resveratrol might be an attractive
small molecule to treat diseases in which aberrant splicing has been implicated, and justify more extensive research on the
effects of resveratrol on the splicing machinery.
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Introduction
In mammals, alternative splicing is the major means by which
cells can generate a diverse repertoire of protein isoforms from a
more limited number of genes [1]. It is estimated that 95% of
human genes are alternatively spliced [2]. The process of
alternative splicing is subject to precise regulation. The utilization
of an alternative exon often depends on the cell type, the
developmental stage and the influence of intracellular signaling
pathways, and this process can occur very rapidly. The importance
of correct splicing is apparent from the growing number of human
diseases that are recognized as being caused by missplicing [3,4].
These diseases result from either mutations, as in the case of
frontotemporal dementia and Parkinsonism linked to chromosome
17, or deregulation of the cellular splicing machinery, as
exemplified by changes in alternative splicing seen in various
cancers [5]. Mutations in cis-elements are often responsible for
aberrant gene expression in various diseases, but tissue-specific
splicing factors, by effects on pre-mRNA processing, have also
emerged as a cause of pathogenic abnormalities in gene expression
[6]. Since different isoforms of proteins can have different
physiological effects [7], alternative splicing has emerged recently
as a new target for pharmacological intervention [8]. Despite the
increasing number of substances, including natural ones such as
caffeine, that have been found to be able to modulate alternative
splicing [9,10,11], toxicity of some and lack of specificity of others
remain major caveats.
Resveratrol is a polyphenolic flavonoid found in grape skins and
seeds, red wine, blueberries, mulberries, peanuts and rhubarb
[12]. Resveratrol affects many major biological processes [13]. In
various ways it has been shown to protect against cardiovascular
disease, type 2 diabetes and neurological disorders (see reviews:
[12,14,15]). The first-observed, and now well-established, effect of
resveratrol was its ability to inhibit the initiation and growth of
tumors in a range of cancer models in mice and rats (reviewed in
[12]).
The molecular mechanisms of action of resveratrol may involve
intracellular pathways that overlap with ones activated by calorie
restriction [16]. It was thought that an early target of resveratrol
was the sirtuin class of NAD
+-dependent deacetylases [17], seven
of which (SIRT 1–7) have been identified in mammals. The extent
to which the sirtuin-activating actions of resveratrol are direct or
indirect is still unresolved, although recent evidence suggests that
indirect effects might be more important [18,19]. The pathways
regulated by sirtuins include gluconeogenesis and glycolysis in the
liver, fat metabolism, stress resistance and cell survival. Down-
stream targets of sirtuins are members of the forkhead box O
(FOXO) group of transcription factors, as well as p53, PGC-1a,
NF-kB, and AGTR1. The result is activation or suppression of
genes involved in apoptosis, antioxidant activity, DNA protection
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targets of resveratrol include kinases such as class IA phosphoino-
sitide 3-kinase and AMP kinase [22,23]. It remains to be shown
whether resveratrol acts by universal, independent or overlapping
mechanisms, but its effects are likely to be mediated by a network
of genes rather than by linear pathways [24].
It has been found recently that resveratrol can bind directly to
DNA and RNA [25]. This led us to ask whether resveratrol might
be involved in alternative splicing. As a key process in the
regulation of gene expression, alternative splicing is able to
influence virtually all cellular processes, including apoptosis, cell
cycling, DNA repair and glucose metabolism [26]. In a cell line
(fibroblast 3813 cells) used as a model of the neurodegenerative
disorder spinal muscular atrophy, resveratrol increased modulated
splicing of survival motor neuron-2 (SMN2), promoting exon 7
inclusion [27]; this effect might be relevant to disease treatment.
The aim of the present study was to test the hypothesis that
resveratrol can modulate alternative splicing of specific primary
mRNA transcripts and do so by altering the levels of specific RNA
processing factors.
Methods
Chemicals
Resveratrol (Sigma) was dissolved in 100% dimethylsulfoxide
(DMSO) to give a 1 M solution. This was diluted with Dulbecco’s
Minimal Essential medium to achieve the final concentrations
described in Results. For control experiments resveratrol was
omitted and the vehicle only was used. All other chemicals were
purchased from Sigma unless stated otherwise.
Cell culture and transient transfection
HEK293 cells (ATCC, CRL-1573) and HeLa cells (ATCC,
CCL-2) were grown in Dulbecco’s Minimal Essential medium
containing sodium pyruvate (GIBCO Invitrogen), supplemented
with 10% fetal bovine serum (FBS; GIBCO Invitrogen) and 5 U/
ml penicillin/streptomycin. All cells were maintained at 37uCi n
an atmosphere of 5% CO2. Prior to transient transfections, cells
were grown to 50–60% confluency in 6-well plates and then
transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. For SIRT1 knockdown, cells were
transfected with 100 pmol of SIRT1-specific siRNA (Stealth
Invitrogen, Cat no. SIRT1-VHS50608) using 4 ml of RNAiMax
(Invitrogen).
Splicing assays
The splicing factors investigated were SMN2, SRp20, CD44v5
and tau. The following minigene plasmids, kindly donated by S.
Stamm, University of Kentucky, were used: pSMN2wt (exons 6–8
SMN2 minigene), pXB(x16) (exons 3–5 SRp20 minigene), pETv5
(exon v5 CD44v5 minigene), and pSVIRB-tau-SV9/10L/11
(exons 9–11 tau minigene) [28]. Splicing assays were performed
essentially as described [28]. Briefly, 2 mg splicing reporter
minigene was transfected into HEK293 or HeLa cells grown on
Figure 1. Resveratrol is able to influence alternative splicing of
specific RNAs. (A) Schematic of minigenes SMN2 and SRp20. Shaded
boxes are alternatively spliceable exons. (B) and (C) Resveratrol caused a
significant dose-dependent increase in exon-inclusion for SMN2 (B) and
SRp20 (C) RNAs, respectively. Upper panels show representative
agarose gels from 3 independent experiments. (D) Representative gels
of splicing assays with tau and CD44v5 minigenes, where ratios of
upper and lower splicing bands did not change in response to
resveratrol. *P,0.05.
doi:10.1371/journal.pone.0028926.g001
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the manufacturer’s instructions. Twenty four hours after transfec-
tion cells were treated with resveratrol (1, 5, 20 and 50 mM final
concentration) for 18 h. RNA was then isolated using 1 ml TRIzol
(Invitrogen). For the SMN2 minigene, RT-PCR was performed
using the primers pcl forward, 59-ggtgtccactcccagttcaa-39, and
SMNex8rev, 59-gcctcaccaccgtgctgg-39, and 30 cycles of 95uC for
30 s, 60uC for 1 min and 72uC for 1 min. For RT-PCR of
minigene SRp20, primers were T7, 59-taatacgactcactataggg-39,
and X16R, 59-cctggtcgacactctagatttcctttcatttgacc-39, and 25 cycles
of 95uC for 30 s, 55uC for 30 s and 72uC for 1 min. PCR products
were then separated in 2% agarose gels. The resultant splicing
band pattern (upper band indicating exon inclusion, lower band
exon spliced) was quantified using Image J software [29].
Statistical analysis was performed using SPSS and analysis of
variance corrected by Dunnett’s test for repeated measures.
Antibodies
Anti-RBM4 (Cat. no 11614-1-AP), anti-PTBP1 (Cat. no 12582-
1-AP), anti-hnRNPA1 (Cat. no 11176-1-AP) and anti-U2AF1
(Cat. no 10334-1-AP) were all from Proteintech Group, Inc. Anti-
HuR (Cat. no 39-0600) was from Invitrogen. Anti-SF2/ASF for
Western blotting was from Invitrogen (Cat. no 32-4500). Anti-
SF2/ASF for immunofluorescence was from Santa-Cruz (Cat.
no sc-10254). Primary antibodies were used at dilutions of 1:200 to
1:3000.
Secondary antibodies were: Alexa Fluor 488 goat anti-rabbit or
anti-mouse IgG, Alexa Fluor 594 goat anti-mouse or anti-rabbit
IgG, Alexa Fluor 594 donkey anti-goat (all from Invitrogen), as
well as sheep anti-mouse horseradish peroxidase (HRP)-linked and
donkey anti-rabbit HRP-linked (GE Healthcare). Secondary
antibodies were used at 1:500 to 1:3000 dilution.
Western blotting
Whole cell protein extracts were prepared using RIPA buffer
(Sigma). Twenty micrograms of extracted proteins were resolved
by 12% SDS-PAGE. Proteins were electroblotted on to a PVDF
membrane (Millipore). Membranes were blocked for one hour in
5% skim milk, then incubated overnight with primary antibody in
blocking solution, followed by 1 h with secondary antibody, before
detection by ECL-plus (GE Healthcare) according to the
manufacturer’s instructions. Images were captured with a
Fluorchem HD2 Imager (AlphaInnotech). Bands were quantified
using Image J software [29].
Intracellular localization studies
For visualization of fluorescence, cells were grown on Lab-Tek
chamber slides (Nunc) and fixed with ice-cold methanol for 2 min.
Following 1 h of blocking with 10% goat serum (Sigma), the cells
were incubated sequentially with primary and secondary antibody
for 1 h each, then stained with 300 nM DAPI (49,6-diamidin-2-
phenylindol) (Molecular Probes, Invitrogen) and mounted with
glycerol/gelatin/PBS (Sigma). Two- and three-channel fluorescent
images were acquired on a Zeiss Axioplan 2 imaging microscope
with an Axiocam HRm camera.
Results
Resveratrol modulates alternative splicing of selected
RNA transcripts
To assess the effect of resveratrol on alternative splicing we
transfected HEK293 cells with different minigene plasmids which
contained alternatively spliceable exons flanked by introns [28].
We then treated the cells with different concentrations of
resveratrol (1, 5, 20 and 50 mM), which were well below toxic
levels, or with vehicle only (control), and after 18 h of treatment
we performed splicing assays. From results of imaging of PCR
products on the agarose gels, percentage exon inclusion was
calculated as the ratio of signal for the upper band and sum of
signals for upper and lower bands.
This experiment showed that resveratrol was able to modulate
alternative splicing in a dose-dependent and RNA-specific manner
(Figure 1), while DMSO vehicle alone had no effect on the splicing
pattern (data not shown). We saw a strong and significant increase
in exon inclusion with SRp20 and SMN2 minigenes (Figure 1A),
but no change in splicing was observed with CD44v5 and tau
minigenes (seen as no change in ratio of upper and lower bands
after resveratrol treatment). This suggests that the effect of
resveratrol is specific for certain pre-mRNA targets, but had no
effect on others. We were able to confirm the effect of resveratrol
on SRp20 and SMN2 minigene pre-mRNA splicing in another
cell type (HeLa cells) (data not shown).
Figure 2. Resveratrol selectively affects specific splicing factor protein levels. (A) Levels of protein of the splicing factors ASF/SF2 and
hnRNPA1 in response to treatment with 0, 1, 5, 20 and 50 mM resveratrol. *Significant P values (,0.05) are indicated. (B) Representative Western blots
showing protein levels of the splicing factors indicated in response to treatment with 0, 1, 5, 20 and 50 mM resveratrol. CoxIV (cytochrome c oxidase
subunit IV) was used as a loading control.
doi:10.1371/journal.pone.0028926.g002
Figure 3. Effect of resveratrol on exon inclusion is rapid and
independent of SIRT1. (A) Exon inclusion increases as early as 8 h
after exposure of cells to 20 mM resveratrol. Shown is a representative
agarose gel of a splicing assay with SMN2. (B) Western blot that shows
SIRT1-specific RNAi reduced SIRT1 protein by 70%, whereas control
siRNA had no significant effect on SIRT1 level. b-tubulin was used as
loading control. (C) Agarose electrophoresis gel following splicing assay
for SMN2 after SIRT1 siRNA and resveratrol treatment at the doses
indicated. This experiment showed that the increase in exon inclusion
was independent of SIRT1 protein levels.
doi:10.1371/journal.pone.0028926.g003
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We hypothesized that resveratrol might be influencing alterna-
tive splicing via an effect on the levels of splicing factor proteins in
cells. To test this we treated HEK293 cells with increasing
amounts of resveratrol and performed Western blotting with
antibodies to a battery of proteins involved in alternative splicing,
namely ASF/SF2 [30], hnRNPA1 [31], HuR [32], RBM4 [33],
PTBP1 [34] and U2AF35 [35]. We found that resveratrol was able
to increase the levels of ASF/SF2, hnRNPA1 and HuR
significantly, but did not alter levels of RBM4, PTBP1 and
U2AF35 (Figure 2). This suggested that resveratrol is capable of
acting selectively so as to alter protein levels of some, but not all,
splicing factors.
The effect of resveratrol on alternative splicing is rapid
and independent of SIRT1
We then tested the time-course of the action of resveratrol on
alternative splicing using the SMN2 minigene. By 8 h of exposure
to 20 mM resveratrol an increase in exon inclusion was evident
(Figure 3A).
SIRT1 is regarded as a major target of resveratrol [36], albeit
by an indirect action, and many of the effects of resveratrol appear
to be mediated by activation of SIRT1 [21,37], which then
activates a number of molecular pathways. We therefore tested
whether the effect of resveratrol on alternative splicing is
dependent on SIRT1. To this end we depleted cells of SIRT1
mRNA by siRNA-mediated knockdown. As shown in Figure 3B,
when using a SIRT1-specific siRNA, SIRT1 protein levels were
reduced by 70% compared to control siRNAs. Co-transfection of
SIRT1-specific siRNA and SMN2 minigene and subsequent
splicing assays failed to show an alteration in the effect of
resveratrol on alternative splicing of SMN2 (Figure 3C). This
suggested that the effect of resveratrol on alternative splicing was
independent of changes in SIRT1 activity or gene expression.
Resveratrol does not alter the intracellular localization of
splicing factors
Splicing factors often have multiple functions within cells, and
their functions can change depending on their localization within
the cell. For instance SR proteins such as ASF/SF2 or SRp20 also
play an important role in the regulation of translation and do so by
relocating from the nucleus to the cytoplasm. We therefore
examined whether resveratrol affected the intracellular localiza-
tion of the splicing factors HuR, hnRNPA, ASF/SF2 and RBM4.
Treatment of HEK293 cells with 20 mM resveratrol for 18 h did
not alter the localization of any of these splicing factors, each of
which remained in the nucleus. Results for HuR, hnRNPA1 and
RBM4 are depicted in Figure 4.
Discussion
The present study has shown that resveratrol can alter the
pattern of alternative pre-mRNA splicing. Our study has also
demonstrated that this effect may involve an influence of
resveratrol on the levels of or activation of specific splicing factors.
Resveratrol promoted exon inclusion in an RNA-specific manner
in that it changed the alternative splicing of two minigenes we
tested (SMN2 and SRp20), but not that of two others. In addition,
resveratrol had a selective effect on the levels of splicing factors,
being able to increase ASF/SF2, hnRNPA1 and HuR proteins,
but not RBM4, PTBP1 and U2AF35. The fact that ASF/SF2 and
hnRNPA1 directly influence the splicing of the specific minigenes
affected by resveratrol, but not that of the minigenes whose
splicing was not affected by resveratrol, supports our findings and
points, at least in part, to the mechanisms involved. In particular, it
was shown earlier that ASF/SF2 and hnRNPA1 are both involved
in exon 7 splicing of SMN2 [38] and that ASF/SF2 is involved in
exon 4 splicing of SRp20 [39]. Thus resveratrol has effects that are
specific for some, but not all, splicing events.
Given the importance of alternative splicing in various diseases,
the identification of non-toxic compounds that inhibit certain
splicing events or stages in the splicing reaction specifically is of
considerable potential importance. The use of RNA-binding
molecules as antibiotics (e.g., gentamicin or tetracycline) illustrates
that drugs can work by targeting RNA and/or RNA-binding
proteins [40]. Furthermore, several low-molecular-mass com-
pounds, such as histone deacetylase inhibitors or kinase/
phosphatase inhibitors, have been identified as modulators of
alternative splicing [11]. The low degree of specificity that these
have on numerous splicing events has to date been problematic
however. Currently, only the use of oligonucleotides allows the
unambiguous, specific targeting of a particular splicing event. The
potential specificity of resveratrol towards a limited repertoire of
splicing factors is therefore of interest and would justify its
examination on a larger scale. Splicing factors, such as ASF/SF2
that are key protein constituents of the core splicing machinery,
are master-regulators of gene expression post-transcriptionally,
Figure 4. Resveratrol does not influence the intracellular
localization of splicing factors. Immunofluorescence results for
HEK293 cells treated with 20 mM resveratrol for 18 h. Shown is
immunofluorescent signal obtained for the specific splicing factor
antibodies indicated. Left panel: untreated control cells. Right panel:
resveratrol-treated cells. The nucleus was stained with DAPI. Shown are
merged images of DAPI staining (blue) and splicing factor staining (red
or green, depending on the secondary antibody used). Scale bar:
20 mm.
doi:10.1371/journal.pone.0028926.g004
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export, nonsense-mediated mRNA decay and translation [41].
Our data showing an effect of resveratrol on specific splicing
factors could suggest that such actions might impact on all of the
above, and in so doing may be responsible in part for the wide
range of beneficial effects that resveratrol has on, for example, the
cardiovascular system, cell growth and metabolism [37].
Our findings are in line with the ability of other botanical
compounds, such as epigallocatechin gallate and curcumin to
induce alternative splicing of full-length SMN2 [27] and of
resveratrol to inhibit tumour necrosis factor-alpha (TNF-a) pre-
mRNA splicing in fish [42]. Our findings in human cells add
impetus to the need for extension of testing of resveratrol on
alternative splicing in mammalian cell lines and cells of other
species.
The effect of resveratrol on pre-mRNA splicing factors shown
here could contribute in large part to the influence that resveratrol
is known to have on phosphorylation of target of rapamycin
(mTOR) [43]. mTOR activates S6K1, which phosphorylates
eIF4B and S6, so promoting translation initiation, and this may be
enhanced by ASF/SF2 [44].
In what way resveratrol is able to affect splicing factor
expression is yet to be determined, but could involve its ability
to activate transcription factors such as FOXOs [45]. Our siRNA-
mediated SIRT1 knockdown experiments show, moreover, that
the effect of resveratrol on splicing and splicing factor levels is not
dependent on SIRT1 expression or activity. Thus SIRT1
deacetylase actions appear not be involved in the effect that
resveratrol has on splicing.
In conclusion, we have found that resveratrol is a specific
modulator of alternative splicing. As such it could be of value in
treatment of diseases caused by aberrant splicing. Larger scale
studies and experiments in animal models of diseases will be
needed to support the clinical utility of this effect of resveratrol.
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